Navigation Links
Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
Date:9/15/2009

PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Tuesday, September 22, 2009 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. Telik Announces Preclinical Presentations at AACR Annual Meeting
3. Telik Announces Patents on Compounds Related to TELINTRA
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
6. Telik Announces Preclinical Presentations at AACR Annual Meeting
7. Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Wine Tasting Event in New York City, with long-time partners The Paul Foundation, ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace is ... styles with unique displacement design elements," said Christina Austin - CEO of Pixel ... from a variety of design styles that include both left aligned and right ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: